US FDA approves leucovorin for ultra- rare genetic disorder causing autism-like symptoms

Core Insights - The U.S. FDA approved leucovorin for treating cerebral folate deficiency, an ultra-rare genetic disorder, but not for broader autism treatment due to insufficient data [1][2][3] - The approval marks a significant shift from previous promises made by government officials regarding the drug's potential for autism treatment [1][2] Drug Approval Details - Leucovorin, a form of folate, is now approved for cerebral folate deficiency based on a systematic review of existing literature rather than clinical trial data [1][2] - The FDA noted that conducting randomized controlled trials was not feasible due to the rarity of the disorder, with only 20 to 50 case studies available [1][2] Market Implications - GSK's Wellcovorin, the branded version of leucovorin, will allow all generic versions to include the new indication, potentially increasing production of the drug [1][2] - The FDA has encouraged drug manufacturers to ramp up production in light of the new approval [1][2] Evidence and Research - Limited evidence exists for leucovorin's efficacy in treating autism, with small studies suggesting a link between autoantibodies and folate deficiency in some children with autism [1][2] - The American Academy of Pediatrics does not recommend routine use of leucovorin for autism due to a lack of substantial evidence [1][2]